Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sernova Corp. (T:SVA)

Business Focus: Medical Devices & Implants

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEDAR
Company Contact
Address: 700 Collip Circle, Ste 114
LONDON ON N6G 4X8
Tel: N/A
Website: https://www.sernova.com
IR: See website
Key People
Frank A. Holler
Executive Chairman of the Board
Philip M. Toleikis
President, Chief Executive Officer, Director
David C Swetlow
Chief Financial Officer
Business Overview
Sernova Corp. is a Canada-based clinical-stage regenerative medicine therapeutics company. The Company is focused on developing and commercializing regenerative medicine therapeutics, including its Cell Pouch and associated technologies, including therapeutic cells and local cellular immune protection. The Cell Pouch is a scalable and implantable medical device. The Cell Pouch is designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of multiple chronic diseases, such as diabetes, hemophilia and thyroid disease. Its Cell Pouch combines with immune protected therapeutic cells, offers a protection from immune system attack. Its regenerative medicine therapeutic approach provides cell therapies, where the cells transplanted within an organ-like the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
Financial Overview
For the nine months ended 31 July 2022, Sernova Corp. revenues was not reported. Net loss increased from C$4.8M to C$16.2M. Higher net loss reflects Research and Dev - Balancing increase from C$1.7M to C$5.7M (expense), Share based compensation in R&D increase from C$81K to C$3.1M (expense), Share-based compensation - options increase from C$22K to C$1.5M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $239.45M as of Jul 31, 2022
Annual revenue (TTM): $0.00M as of Jul 31, 2022
EBITDA (TTM): -$18.35M as of Jul 31, 2022
Net annual income (TTM): -$18.39M as of Jul 31, 2022
Free cash flow (TTM): -$12.01M as of Jul 31, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 303,332,686 as of Oct 31, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization